Globalization and the Future of Medical Writing

Medical writers play a key role in global regulatory submissions across the pharmaceutical industry. Before the COVID pandemic, many companies were working toward development of global regulatory submissions, with their medical writers playing a key role in this process. During the pandemic, the need for greater collaboration in fully remote working conditions, inclusion and transparency, and the unprecedented demand for speed and quality of clinical development has brought global ways of working into even greater focus. A panel of medical writers, including department and regional heads and subject matter experts, were invited to consider how other influences on our industry may drive the evolution of medical writing yet further as a global profession in the coming years. This article summarizes the panel’s responses to 5 questions on the future direction of the profession.
Contributors include:
Jeannene Butler, Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ
Kelley Hill, Alexion, AstraZeneca Rare Disease, Boston, MA
Garima Pallavi, Parexel International India Development & Commercialization Safety Services Private Limited, Bangalore, India
Grishma Kanchan, Parexel International India Development & Commercialization Safety Services Private Limited, Bangalore, India
Jonathan Mackinnon, Parexel International S.L., Madrid, Spain
Renee Primus, Bristol Myers Squibb, Princeton, NJ
Matthew Renda, Alexion, AstraZeneca Rare Disease, Boston, MA
Linda Yih, Parexel International LLC
Nan Wang, Bayer Healthcare Co. Ltd., Beijing, China